tbuckley/cabot-search huggingface dataset:
Utilization and costs of supportive medications among patients with metastatic breast (mBC) or colorectal cancer (mCRC)
Authors: U. Dugan, R. W. Baran, J. Barron, A. W. Law, W. J. Waugh, W. D. Grochulski, G. Cummins
Journal: Journal of Clinical Oncology (2004)

6099 Background: Supportive medications for patients receiving chemotherapy can increase complexity of care and healthcare costs. Our objective was to examine the utilization and costs of supportive medications for patients treated with oral capecitabine versus comparison intravenous (IV) chemotherapy for mBC or mCRC. Methods: We conducted a retrospective analysis of medical and pharmacy claims of over six million members from three managed care organizations between January 1, 2000 and June 30, 2002. Patient cohorts, capecitabine versus IV chemotherapy, were identified through (1) ICD-9 codes for mBC or mCRC and (2) the use of chemotherapy. Results on patients with mBC were separated into those using capecitabine as first-line or second-line therapy. For second-line mBC therapy, capecitabine was compared with two regimens: (1) prior anthracycline and prior taxane; (2) prior anthracycline or prior taxane. For mCRC, capecitabine was compared to 5-FU or irinotecan. Supportive medications were identified through NDC codes for seven categories: leucovorin, antiemetics, analgesics, antibiotics, antidiarrheals, hematopoietics, and erythropoietics. Utilization and costs of supportive medications were assessed per treatment cycle. Results: IV therapies for second-line mBC and mCRC had significantly greater utilization and costs of supportive medications per cycle compared to capecitabine. Patients using IV regimens as first-line mBC therapy also had higher odds of utilizing supportive medications (odds ratio=1.76). Conclusions: Compared with oral capecitabine, patients treated with comparison IV chemotherapy for mBC or mCRC had significantly higher odds ratio of utilizing supportive medications and consequently, incurred higher cost. Capecitabine not only decreases use of supportive medications and reduces cost of care but also promotes less complex therapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Laboratories, Inc.
Development of prognostic biomarker in pathologic stage I NSCLC patients: Protein expressions involving in DNA damage response.
Authors: J. S. Ryu, C. Choi, S. Yang, H. Nam, H. Kim, M. H. Lee
Journal: Journal of Clinical Oncology (2011)

7578 Background: Although mechanism of proteins involving DNA damage-response (DDR) pathway remains to be further elucidated, these proteins have role of suppressing tumor development or progression. Current guidelines has argued that postoperative treatment is not beneficial for patients with stage I non-small cell lung cancer (NSCLC). Therefore, development of prognostic biomarker is very important clinical issue in stage I NSCLC. Methods: We constructed tissue microarrays with paraffin-embedded primary lung cancer tissue from 889 pathologic stage I NSCLC patients (401 squamous cell carcinoma, SQC 488 adenocarcinoma, ADC) who received completely surgical resection. Expression levels of 12 proteins (ATM, ATMpS1981, γH2AX, MCPH1/BRIT1, 53BP1, 53BP1pS25, Chk2, Chk2pT68, MDC1, MDC1pS964, BRCA1pS1423, ERCC1), clinicopathologic variables and overall survival were investigated. Results: Overall survival of a total of 889 patients was 128 months (MST: 123.8 months in SQC vs NR in ADC, log-rank P =.1337). Higher level of expressions in γH2AX, BRCA1pS1423 or ERCC1 were significantly associated with better survival in the patients after adjustment for significant clinicopathologic variables [aHR (95%CI), Cox P: 1.271 (1.005 to 1.680), 0.045 for γH2AX, 1.348 (1.067 to 1.704) for BRCA1pS1423, 0.012 and 1.326 (1.042 to 1.689), 0.022 for ERCC1]. When analyzed by cell types, higher level of expressions in γH2AX, Chk2pT68 or ERCC1 were shown to be good prognostic factors even after adjustment for significant clinicopathologic variables in SQC patients [aHR (95%CI), Cox P: 1.537 (1.096 to 2.157), 0.013 for γH2AX, 1.618 (1.120 to 2.336), 0.010 for Chk2pT68 and 1.689 (1.197 to 2.383), 0.003 for ERCC1]. However these effects (on survival) were not shown to be in ADC patients. Conclusions: The proteins’ expressions involving DDR pathway as well as ERCC1 are determinant of survival in stage I SQC patients that could be helpful in classifying the patients into groups of high or low risk for death.
Abstract 12664: Anomalous Aortic Origin of Coronary Arteries: A Single Center Experience
Authors: Assunta Fabozzo, Matthew DiOrio, Jane W Newburger, Andrew J Powell, Hua Liu, Francis Fynn-Thompson, Stephen P Sanders, Frank A Pigula, Pedro J del Nido, Meena Nathan
Journal: Circulation (2014)

Background: Anomalous aortic origin of the coronary arteries (AAOCA) has an estimated prevalence of 0.1%-0.3%. Data on risks and benefits of surgery vs. observation to guide management decisions are limited. Methods: In a single center, we included patients (pts) with AAOCA with right (R) and/or left (L) intramural (IM), interarterial IA) or intraconal (IC) course from 1996-2014. We excluded pts with benign CA anomalies or major structural heart disease. Results: Among 154 pts, median age at diagnosis (dx) was 8.5 (range 0.1-50) yrs, median f/u was 1.92 (0.1-12.8) yrs, and 65% were male. The AAOCA course was IA in 116 (75%), IM in 52 (34%) and IC in 3 (2%). AAORCA was present in 126 (82%), of whom (51) 40% had repair. AAOLCA was present in 28 (18%), of whom 20 (71%) had repair; of the remaining 8, 2 had intraconal course; 2 were second opinions, 1 had Friederich’s ataxia, and 3 are awaiting surgery. In the surgical group, all had IA/IM CAs, and CA unroofing was performed in 90%, of whom 50% also had resus...
Abstract 16635: Exercise Magnetic Resonance Imaging to Identify Impaired Pulmonary Vascular and Right Ventricular Reserve in Patients With Normalized Resting Hemodynamics After Pulmonary Endarterectomy
Authors: Guido Claessen, Andre La Gerche, Steven Dymarkowski, Piet Claus, Marion Delcroix, Hein Heidbuchel
Journal: Circulation (2014)

Introduction: Although pulmonary endarterectomy (PEA) is the most efficacious treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), patients with normalized pulmonary vascular resistance (PVR) after successful PEA do not always regain a normal exercise capacity.

Methods: 26 healthy controls, 15 CTEPH patients and 7 patients with a normalized mean pulmonary artery pressure (mPAP) post-PEA (25 mmHg) first underwent cardiopulmonary exercise testing to determine peak VO2 and maximal power (Pmax). Then, cardiac MRI with simultaneous invasive mPAP measurement was performed during supine bicycle exercise at 25%, 50% and 66% of Pmax. Biventricular volumes were obtained from endocardial tracings using in-house developed software. Cardiac output (CO) was calculated as stroke volume x heart rate, ejection fraction (EF) as SV / EDV %, tPVR as mPAP / CO and PA compliance (CPA) as stroke volume / PA pulse pressure.

Results: In post-PEA patients, resting tPVR was higher than in controls (P=0.01) but lower than in CTEPH patients (P<0.0001). The slope of mPAP/CO plots was steeper in post-PEA patients than in controls (P<0.0001) and similar to CTEPH (Figure 1A). Relative to controls, resting RVEF was reduced in CTEPH (P<0.0001), but not in post-PEA patients (P=1.0), whilst peak exercise RVEF was reduced both in post-PEA and CTEPH patients (both P<0.0001; Figure 1B). Resting CPA was higher in controls than post-PEA and CTEPH patients (P<0.0001) and correlated strongly with VO2max (R2=0.82, P<0.0001). Despite controls demonstrating the greatest reductions in CPA during exercise, values still remained higher than the resting values in CTEPH and post-PEA patients (p<0.01).

Conclusion: Despite normal resting measures, pulmonary vascular and RV responses to exercise are abnormal in post-PEA patients. Although CPA decreases during exercise in healthy subjects, CPA is significantly lower in CTEPH and post PEA patients at rest and throughout exercise.

   ![][1]  [1]: /embed/graphic-1.gif
Abstract 15291: The Soluble Guanylyl Cyclase (sGC) Activator BAY 58-2667 Selectively Limits Cardiomyocyte Hypertrophy - A Potential Therapeutic Advantage for Managing Left Ventricular Hypertrophy (LVH)
Authors: Rebecca H Ritchie, Jennifer C Irvine, Virat Ganthavee, Jane E Love, Amy E Alexander, John D Horowitz, Johannes-Peter Stasch, Barbara K Kemp-Harper
Journal: Circulation (2012)

Evidence suggests cGMP is a negative regulator of LVH. Traditional nitrovasodilators are not indicated for managing LVH, due to the combined phenomena of nitrate tolerance as well as NO• resistance, both in part due to oxidative stress. The direct consequences of the NO•-independent sGC activator BAY 58-2667 on LV remodeling, independent of hemodynamic load, have however not been investigated. We tested the hypothesis that BAY 58-2667 directly inhibits cardiomyocyte hypertrophy in vitro. Concomitant impact of BAY 58-2667 on fibroblast proliferation, and insights into potential mechanisms of action, were also sought. Results were compared to the sGC stimulator BAY 41-2272. BAY 58-2667 (0.01-0.30µM, 48h) elicited concentration-dependent antihypertrophic actions in neonatal rat cardiomyocytes, inhibiting endothelin-1 (ET1, 60nM)-mediated increases in cell size and de novo protein synthesis, as well as suppressing ET1-induced cardiomyocyte superoxide (•O2-) generation. This was accompanied by markedly increas...
Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2
Authors: S. E. Witta, V. Franekova, K. Yoshida, I. Igolnikov, B. Frederick, M. Varella-Garcia, P. A. Bunn, F. R. Hirsch
Journal: Journal of Clinical Oncology (2009)

e14566 Background: We previously demonstrated the synergistic effect of the histone deacetylase inhibitor SNDX-275 and gefitinib in non-small cell lung cancer (NSCLC) cell lines lacking E-cadherin expression. We evaluated the combination effect of SNDX- 275 with erlotinib or lapatinib in lung, head and neck (H&amp;N) and breast cancer cell lines resistant to erlotinib or lapatinib(IC50&gt; 1uM) and expressing Her2. Methods: This study included 10 H&amp;N and 17 NSCLC cell lines, 2 breast cancer cell lines with expressing Her2 (SK BR3, MCF7) and one lacking Her2 expression, MDA-MB231. Cell lines were incubated for 5 days with increasing concentrations (0.16, 1 and 6μM) of SNDX-275, lapatinib and erlotinib alone or in combination. The growth inhibitory effect was analyzed with MTT assay. The combination drug effect was evaluated using CalcuSyn (Cambridge, UK). E-cadherin and Her2 expression was evaluated using microarray analysis and RT-PCR. Her2 was considered positive if the relative expression was &gt;300 by RT-PCR. Protein expression was analyzed with western blots. Results: Among the 17 NSCLC and 10 H&amp;N cell lines 16 (12 NSCLC and 4 H&amp;N) had positive Her2 RNA expression. 2 NSCLC (A549, H1703) and 2 H&amp;N (UMSCC10, UMSCC19) were resistant to erlotinib or lapatinib (IC50&gt;1μM). The 2 breast cancer cell lines 2, MCF7 and MDA-MB-321, were resistant to erlotinib and lapatinib. SNDX-275 increased the expression of E-cadherin in 5 of the 6 cell lines selected (A549, H1703, UMSCC19, MCF7 and MDA- MB-321). Synergistic effect of SNDX-275 1μM and lapatinib 1μM was detected in the MCF7, UMSCC10, UMSCC19 cell lines (Combination Index, CI: 0.09, 0.9, 0.67; respectively), while SNDX-275 1μM and erlotinib 1μM were synergistic in MCF7, MDA-MB-321, H1703 and A549 (CI: 0.2, 0.95, 0.58, 0.32; respectively). Conclusions: The combination of SNDX-275 and erlotinib or lapatinib is active in breast, NSCLC, H&amp;N cell lines resistant to either drug alone. [Table: see text]
Resiliency among nursing staff in an inpatient medical oncology unit.
Authors: Alaina L Carr, Lara Traeger, Barbara J. Cashavelly, William F. Pirl
Journal: Journal of Clinical Oncology (2015)

24 Background: Inpatient medical oncology nursing staff members often care for seriously ill patients with complex needs, and are at particular risk for burn out. This qualitative study explored the experiences of registered nurses (RN) and nurse practitioners (NP) on an inpatient medical oncology unit. We identified factors influencing resiliency in caring for oncology inpatients on a daily basis. Methods: We conducted in-depth qualitative interviews with 24 RNs and 13 NPs working on an inpatient medical oncology unit at an academic medical center. A semi-structured interview guide was used to elicit perspectives on facilitators and barriers to resilience in caring for oncology patients. Content analysis was conducted to identify themes between RNs and NPs. Results: Both RNs and NPs described being emotionally affected by daily experiences with patient suffering and death. However, they commonly identified that relationships with patients at the end of life (EOL) were sources of profound inspiration; and they felt privileged to engage with patients during this significant phase of their lives. Factors that negatively impacted resilience included a) barriers to communicating with team members and patients about EOL issues, b) successions of acutely ill patients on the unit, and c) work-life balance issues in the context of intensive shift schedules. Following emotionally difficult days, staff found motivation to return to work the next day through: a) mutual understanding and support from unit coworkers, b) sense of connection to seriously ill patients and their families, and c) general perception of oncology nursing as part of one’s identity. Conclusions: Nursing staff were intrinsically motivated to connect with seriously ill patients and to provide meaningful EOL care. Connections with coworkers and patients/families and personal identification with the role of oncology nursing helped staff to return to work after emotionally difficult experiences on the unit. Results identify potential targets for intervention to increase resiliency, including increasing workplace cohesion, communication and support within the unique inpatient milieu.
The K751Q polymorphism of XPD gene in lung cancer patients receiving platinum-based chemotherapy
Authors: U. Ricardi, S. Regazzoni, P. Ghio, D. Giachino, M. De Marchi, S. Novello, G. Selvaggi, G. V. Scagliotti
Journal: Journal of Clinical Oncology (2004)

2500 Background: Cisplatin and derivatives represent the cornerstone drugs in lung cancer treatment. Nevertheless, treatment related toxicities are sometime relevant and survival is still limited. Platinum-based compounds act by forming DNA adducts and cross-links which are recognized and repaired through the NER repair pathway. The efficacy of platinum therapy may be affected by polymorphisms of the XPD protein, an essential participant in transcription-coupled repair. We have prospectively investigated the A>C Single Nucleotide Polymorphism (SNP) at exon 23, which results in a K751Q substitution, because of its high allele frequency and loss of functional activity. Methods: 196 consecutive lung cancer patients were prospectively enrolled: 82% males, 46% currently and 37% previous smokers, 82% non-small cell lung cancer. Among them, 128 out of 196 received cisplatin or derivatives, mainly in combination with gemcitabine. The control group was represented by 181 healthy medical students. As December 2003 median follow up period is 170 days. The SNP was characterized by digesting the amplified exon 23 with PstI using PCR-RFLP technique Results: Patients genotype frequencies (KK 42%, K/Q 46%, Q/Q 12%) were not significantly different from those observed in healthy volunteers (K/K 38.4%, K/Q 43.4%, Q/Q 18.2%). The XPD genotype was not associated with response to platinum-treatment and the smoking habit. In QQ homozygotes, relapses were more frequent, though not significantly (Odds Ratio= 2.7 p= 0,19), while deaths during follow up were significantly more frequent (35% vs 9% in KQ and 13% in KK, O.R of QQ vs KQ+KK= 4.5, 95% C.I. 1.4–14.4, p= 0.007). At the multivariate analysis the increased risk of death was confirmed after adjusting the XPD genotype for histological subtype. Conclusions: The XPD K751Q polymorphism may be an important marker associated with some aspects of the response to platinum chemotherapy, and may predict the non-responsiveness in a subgroup of patients who should be addressed to alternative non-platinum based treatments. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly Italian Research Council
Can Nonhormonal Treatments Dial Down the Heat During Menopause?
Authors: Julie A. Jacob
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 12206: Mobilization of Bone Marrow-Derived Endothelial Progenitor Cells and Re-Endothelialization After Coronary Stent Implantation -Assessment in Second Generation Drug Eluting Stents-
Authors: Nasuno Takahisa, Michiaki Tokura, Michiya Kageyama, Shigeru Toyoda, Isao Taguchi, Shichiro Abe, Ryoichi Sohma, Koichi Node, Teruo Inoue
Journal: Circulation (2013)

Although drug-eluting stent (DES) technology has demonstrated reduced restenosis, a new concern is that DESs may impair re-endothelialization, which is essential for the wound healing process in th...
Abstract 13826: Effect of Treatment with 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) on Coronary Plaque Progression: A Serial CT Angiography Study
Authors: Matthew J Budoff, Reuben Ram, Vahid Larinjani, Sachidanand Prabhu, Christopher Dailing, Nina Ram, Armand Ardestani, Naser Ahmadi, Reda Ibrahim, Jean Gregoire, Phillipe L L'Allier, Josephine Pressacco, Jean-Claude Tardif
Journal: Circulation (2012)

Background: Statins have been shown to reduce plaque progression. Little data on plaque progression is available with anti-inflammatory agents. Production of leukotrienes by 5-lipoxygenase (5-LO) h...
1130 HIGH DOSE ORAL THIOACETAMIDE INDUCES IRREVERSIBLE HEPATIC FIBROSIS IN MICE
Authors: P. Ramachandran, A. Pellicoro, A.J. Robson, C.M. Payne, T. Matsumoto, R.L. Aucott, S.J. Forbes, J.P. Iredale
Journal: Journal of Hepatology (2013)
T-Cell Therapy for Multiple Myeloma Using NY-ESO-1+ T-Cell Antigen Presenting Cells (T-APC) Combined with Adoptive Cellular Transfer (ACT) to Augment Immunotherapy
Authors: Krina K. Patel, Simon Olivares, Lenka V. Hurton, Helen Huls, Muzaffar H. Qazilbash, Richard E. Champlin, Laurence JN Cooper
Journal: Blood (2014)
Sunitinib and bevacizumab in advanced solid tumors: A phase I trial
Authors: M. M. Cooney, J. A. Garcia, P. Elson, T. Mekhail, R. Dreicer, C. J. Nock, J. A. Bokar, A. Tyler, K. Beatty, R. M. Bukowski, B. I. Rini
Journal: Journal of Clinical Oncology (2008)

3530 Background: Sunitinib is an oral multi-targeted inhibitor of VEGFR-2 and related receptors. Bevacizumab is an antibody that binds to VEGF. The safety, tolerability, and clinical activity of sunitinib plus bevacizumab was assessed. Methods: Patients (pts) with advanced solid tumors, adequate organ function, and ECOG performance status of 0–1 were eligible. Pts received sunitinib daily for 28 days followed by 14 days off. Bevacizumab was administered IV on D1, 15, and 29 of a 42-day cycle. Three pts received 25 mg sunitinib / 5 mg/kg bevacizumab, seven pts received 37.5/5, three pts 37.5/10, thirteen pts 50/10 and six pts 50/5. DLTs were defined in cycle 1 as any grade (G) 4 toxicity any G3 cardiac event, HTN unable to be controlled to < 160/90 with medications, any arterial thromboembolic event, any G3 non-cardiac toxicity that did not resolve to ≤ G 1 within 6 weeks, and proteinuria > 3.5 gm/24 hr. Results: 32 pts have enrolled (22 male and 10 female). Tumor types included renal (7), adrenal (5), melanoma (3), bladder, thyroid, lung, small bowel, testis and prostate (2 each) as well as, gastric, breast, unknown primary, hemangiopericytoma and pancreas (1 each). Median age is 55 years (range, 27- 83), median number of prior systemic therapies was 2 (range, 0–3). Seventeen pts (53%) have discontinued treatment (8 PD, 6 toxicity and 3 withdrew consent). Pts have received a median of 2 cycles of treatment (range, 1+-9+). One pt experienced a DLT (G4 HTN) at dose level +1 (37.5 mg sunitinib and 5mg/kg bevacizumab). G3 episodes of bladder hemorrhage, G3 neck soft tissue necrosis, and G3 rectal necrosis were observed. Other G3 toxicities included HTN (13 pts), hypophosphatemia (4 pts), PPE and hyponatremia (2 pts each), and one episode each of fatigue, hypokalemia and thrombocytopenia. Most common G1–2 toxicities included anorexia, diarrhea, fatigue, nausea and stomatitis. To date, no clinical or laboratory evidence of microangiopathic hemolytic anemia has been observed. Of 23 pts evaluable for response, 7 achieved a PR (30%; 3 renal, 2 bladder, 1 melanoma and 1 thyroid) and 11 achieved SD. Conclusions: This combination is tolerable at full doses without unexpected toxicities. Anti-tumor activity was observed across many solid tumors. Supported by the NCI/CTEP Grant U01 CA62502 and a Pfizer Research Grant. No significant financial relationships to disclose.